Elevated tumor mutational burden and prolonged clinical response to anti-PD-L1 antibody in platinum-resistant recurrent ovarian cancer

• We report an ovarian cancer patient with a prolonged response to immunotherapy. • Comprehensive genomic profiling may detect patients who benefit from immunotherapy. • Mutational burden thresholds for ovarian cancer may be lower than other cancers.

Detalles Bibliográficos
Autores principales: Morse, Christopher B., Elvin, Julia A., Gay, Laurie M., Liao, John B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510487/
https://www.ncbi.nlm.nih.gov/pubmed/28736741
http://dx.doi.org/10.1016/j.gore.2017.06.013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5510487/
https://www.ncbi.nlm.nih.gov/pubmed/28736741
http://dx.doi.org/10.1016/j.gore.2017.06.013

Ejemplares similares